Minimal clinically important difference in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disease with an estimated median survival of 2–5 years and a significant impact on quality of life (QoL). Current approved medications, pirfenidone and nintedanib, have shown a reduction in annual decline of forced vital ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Mohleen, Marts, Lucian, Kempker, Jordan A., Veeraraghavan, Srihari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291912/
https://www.ncbi.nlm.nih.gov/pubmed/34295421
http://dx.doi.org/10.1183/20734735.0345-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291912/
https://www.ncbi.nlm.nih.gov/pubmed/34295421
http://dx.doi.org/10.1183/20734735.0345-2020

Ejemplares similares